Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:CADL NASDAQ:EXOZ NASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.69-1.7%$3.99$2.90▼$11.16$325.24M0.183.72 million shs1.28 million shsCADLCandel Therapeutics$5.00-14.6%$5.99$3.79▼$14.60$274.50M-0.91.02 million shs2.05 million shsEXOZeXoZymes$10.02+3.4%$9.83$8.50▼$23.99$84.07MN/A14,075 shs3,457 shsLRMRLarimar Therapeutics$3.85+3.8%$3.52$1.61▼$9.50$319.12M0.911.09 million shs1.02 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.09%+9.01%+3.88%-31.69%-44.03%CADLCandel Therapeutics+1.21%-1.68%-6.84%+4.64%-13.19%EXOZeXoZymes-0.10%-0.05%-3.77%-28.75%+968,999,900.00%LRMRLarimar Therapeutics+2.49%-4.13%+7.85%+51.43%-53.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.9723 of 5 stars4.32.00.00.01.81.70.6CADLCandel Therapeutics2.103 of 5 stars3.51.00.00.02.21.70.6EXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/ALRMRLarimar Therapeutics3.1322 of 5 stars3.63.00.00.03.23.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.57Moderate Buy$17.40372.18% UpsideCADLCandel Therapeutics 3.00Buy$20.00299.68% UpsideEXOZeXoZymes 0.00N/AN/AN/ALRMRLarimar Therapeutics 3.10Buy$18.43378.66% UpsideCurrent Analyst Ratings BreakdownLatest EXOZ, CADL, ALT, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CADLCandel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.00 ➝ $7.008/15/2025LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $18.008/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,261.91N/AN/A$1.83 per share2.01CADLCandel Therapeutics$120K2,289.33N/AN/A$1.64 per share3.05EXOZeXoZymes$70K1,200.97N/AN/A$0.86 per share11.65LRMRLarimar TherapeuticsN/AN/AN/AN/A$1.45 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)CADLCandel Therapeutics-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/A-134.50%-81.63%N/ALRMRLarimar Therapeutics-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)Latest EXOZ, CADL, ALT, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CADLCandel Therapeutics-$0.17-$0.09+$0.08-$0.09N/AN/A8/14/2025Q2 2025LRMRLarimar Therapeutics-$0.47-$0.41+$0.06-$0.41N/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/12/2025Q2 2025EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44CADLCandel Therapeutics0.017.047.04EXOZeXoZymes0.016.196.19LRMRLarimar TherapeuticsN/A5.465.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CADLCandel Therapeutics13.93%EXOZeXoZymesN/ALRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%CADLCandel Therapeutics16.60%EXOZeXoZymes72.41%LRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableCADLCandel Therapeutics6054.90 million45.78 millionOptionableEXOZeXoZymes298.39 million2.31 millionN/ALRMRLarimar Therapeutics3082.78 million79.05 millionOptionableEXOZ, CADL, ALT, and LRMR HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Decreases Stock Holdings in Larimar Therapeutics, Inc. $LRMRSeptember 3 at 5:25 AM | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $18.43 Average Target Price from AnalystsAugust 23, 2025 | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comQ4 Earnings Estimate for LRMR Issued By Leerink PartnrsAugust 20, 2025 | marketbeat.comQ3 EPS Forecast for Larimar Therapeutics Lifted by AnalystAugust 19, 2025 | marketbeat.comWilliam Blair Analysts Lift Earnings Estimates for LRMRAugust 19, 2025 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Issues Earnings ResultsAugust 17, 2025 | marketbeat.comResearch Analysts Set Expectations for LRMR FY2028 EarningsAugust 17, 2025 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $18.00 by Analysts at JMP SecuritiesAugust 17, 2025 | marketbeat.comLeerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)August 16, 2025 | theglobeandmail.comLarimar Therapeutics (LRMR) Gets a Buy from Truist FinancialAugust 16, 2025 | theglobeandmail.comLarimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA FilingAugust 16, 2025 | msn.com3 Best Stocks to Buy Now, 8/15/2025, According to Top AnalystsAugust 15, 2025 | msn.comLarimar Therapeutics Announces $64.4 Million Stock OfferingAugust 15, 2025 | theglobeandmail.comLarimar Therapeutics price target lowered to $18 from $22 at Citizens JMPAugust 15, 2025 | msn.comLarimar Therapeutics Advances Nomlabofusp Program Amid Financial LossesAugust 14, 2025 | tipranks.comLarimar Beats Q2 Loss EstimatesAugust 14, 2025 | aol.comALarimar Therapeutics reports Q2 EPS (41c), consensus (49c)August 14, 2025 | msn.comLarimar Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comAltium Capital Management LLC Reduces Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)August 14, 2025 | marketbeat.comLarimar Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s EndBy Thomas Hughes | August 19, 2025EXOZ, CADL, ALT, and LRMR Company DescriptionsAltimmune NASDAQ:ALT$3.68 -0.07 (-1.73%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Candel Therapeutics NASDAQ:CADL$5.00 -0.86 (-14.61%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.eXoZymes NASDAQ:EXOZ$10.02 +0.33 (+3.41%) As of 02:14 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Larimar Therapeutics NASDAQ:LRMR$3.85 +0.14 (+3.77%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
